Arcutis Biotherapeutics Inc. (ARQT) PT Raised to 'Street High' $80 at Cowen
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
- Intel shares fall as competitor reports record results
- Qualcomm (QCOM) Reports In-Line Q4 EPS, Beats on Revenue; Offers Q1 Guidance
- Array Technologies and Shoals Technologies agree to stock-for-stock merger
- AMD gets bullish pre-earnings call from Lynx as server CPU demand accelerates
- SanDisk shares fall on election and chip sector pressure
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Arcutis Announces Positive Topline Results from Pivotal DERMIS-1 and -2 Phase 3 TrialsĀ of Topical Roflumilast Cream (ARQ-151) in Plaque Psoriasis
February 1, 2021 7:30 AM ESTRoflumilast cream demonstrated statistically significant superiority over vehicle on primary endpoint of IGA SuccessFavorable safety and tolerability profile in this patient populationNew Drug Application (NDA) submission anticipated in the second half of... More



